{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T20:59:31Z","timestamp":1780779571543,"version":"3.54.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.neurot.2026.e00903","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T18:03:24Z","timestamp":1775844204000},"page":"e00903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The wearing-off effect with natalizumab: Back to the drawing board"],"prefix":"10.1016","volume":"23","author":[{"given":"Saira","family":"Afzal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devon S.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.neurot.2026.e00903_bib1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2026.e00903_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1477-7525-10-155","article-title":"Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study","volume":"10","author":"Kamat","year":"2012","journal-title":"Health Qual Life Outcome"},{"issue":"14","key":"10.1016\/j.neurot.2026.e00903_bib3","first-page":"1248","article-title":"Natalizumab-associated wearing-off phenomenon","volume":"75","author":"Ratchford","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2026.e00903_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jneuroim.2017.06.012","article-title":"Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis","volume":"310","author":"Villani","year":"2017","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurot.2026.e00903_bib5","doi-asserted-by":"crossref","first-page":"17654","DOI":"10.1038\/s41598-024-68322-w","article-title":"Insight into motor fatigue mechanisms in natalizumab treated multiple sclerosis patients with wearing off","volume":"14","author":"Leodori","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00903_bib6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/ACO.0b013e3282b972fb","article-title":"Nocebo hyperalgesia: how anxiety is turned into pain","volume":"20","author":"Colloca","year":"2007","journal-title":"Curr Opin Anaesthesiol"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00903_bib7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/jcph.894","article-title":"Population pharmacokinetics and target engagement of natalizumab in patients with multiple sclerosis","volume":"57","author":"Muralidharan","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.neurot.2026.e00903_bib8","first-page":"101957","article-title":"End of dose interval symptoms in patients treated with natalizumab: a role for serum cytokines?","volume":"40","author":"Dekeyser","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00903_bib9","article-title":"The patient-reported wearing-off phenomenon with monoclonal antibody treatments for multiple sclerosis","volume":"10","author":"Marian","year":"2024","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00903_bib10","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing on 4-week dosing (NOVA): a randomised, controlled, open-label trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2026.e00903_bib11","doi-asserted-by":"crossref","first-page":"122930","DOI":"10.1016\/j.jns.2024.122930","article-title":"Natalizumab extended interval dosing: what about wearing-off effect?","volume":"458","author":"Bernardes","year":"2024","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00903_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2026.e00888","article-title":"No association between the wearing-off effect and \u03b14-integrin receptor saturation in natalizumab-treated patients with relapsing-remitting multiple sclerosis","volume":"23","author":"Freeman","year":"2026","journal-title":"Neurotherapeutics"},{"issue":"17","key":"10.1016\/j.neurot.2026.e00903_bib13","doi-asserted-by":"crossref","first-page":"e1579","DOI":"10.1212\/WNL.0000000000008357","article-title":"The natalizumab wearing-off effect: end of natalizumab cycle, recurrence of MS symptoms","volume":"93","author":"van Kempen","year":"2019","journal-title":"Neurology"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T20:26:09Z","timestamp":1780777569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926000735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1878747926000735"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00903","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The wearing-off effect with natalizumab: Back to the drawing board","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00888","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00903"}}